| |
Total (%)
|
CD56+ group (%)
|
CD56- group (%)
|
p value
|
|---|
|
Sex
|
64
|
13
|
51
|
0.706
|
|
Male
|
47 (73.4)
|
9 (69.2)
|
38 (74.5)
| |
|
Female
|
17 (26.6)
|
4 (30.8)
|
13 (25.5)
| |
|
Age
|
64
|
13
|
51
|
0.427
|
|
Median
|
23
|
20
|
23
| |
|
Range
|
5–74
|
8–60
|
5–74
| |
|
Stage
|
46
|
13
|
33
|
0.015*
|
|
I-II
|
26 (56.5)
|
11 (84.6)
|
15 (45.5)
| |
|
III-IV
|
20 (43.5)
|
2 (15.4)
|
18 (54.5)
| |
|
Site
|
64
|
13
|
51
|
0.038*
|
|
Nodal
|
26 (40.6)
|
2 (15.4)
|
24 (47.1)
| |
|
Extranodal
|
38 (59.4)
|
11 (84.6)
|
27 (52.9)
| |
|
B symptoms
|
37
|
12
|
25
|
0.308
|
|
With
|
20 (54.1)
|
5 (41.7)
|
15 (60.0)
| |
|
Without
|
17 (45.9)
|
7 (58.3)
|
10 (40.0)
| |
- * Statistically significant p values are in bold
